Key result
Transcatheter aortic valve replacement successfully treated a prohibitive-risk patient with Corynebacterium striatum prosthetic valve endocarditis and severe aortic regurgitation, with normal valve function at 12 months.
Why the study?
Can off-label valve-in-valve TAVR be successfully used to treat prosthetic valve endocarditis complicated by severe aortic insufficiency and cardiogenic shock in a prohibitive-risk surgical candidate?
Case Report (n=1)
No
Can off-label valve-in-valve TAVR be successfully used to treat prosthetic valve endocarditis complicated by severe aortic insufficiency and cardiogenic shock in a prohibitive-risk surgical candidate?
Off-label valve-in-valve TAVR may be a feasible salvage therapy for prosthetic valve endocarditis complicated by severe aortic insufficiency and cardiogenic shock in prohibitive-risk surgical candidates.
May offer salvage option in prohibitive-risk prosthetic valve endocarditis; leaves open need for prospective evaluation before wider use.
We describe the case of a 69-year-old man with a history of bioprosthetic aortic valve replacement who presented with Corynebacterium striatum prosthetic valve endocarditis (PVE) complicated by severe aortic insufficiency with refractory cardiogenic shock despite antibiotic therapy. He was considered a prohibitive-risk surgical candidate due to co-morbid conditions and off-label valve-in-valve transcatheter aortic valve replacement (TAVR) was performed after detailed multidisciplinary evaluation. He recovered well without recurrent infection following completion of antibiotics and transthoracic echocardiogram at 12 months showed a normal functioning prosthetic valve. To our knowledge, this is the first reported case of native or PVE treated with TAVR.
No takes yet. Share an insight, caveat, or question.
Naqvi et al. (2018) conducted a case report in Corynebacterium striatum prosthetic valve endocarditis with severe aortic regurgitation (n=1). Transcatheter aortic valve replacement (TAVR) was evaluated on Clinical recovery and prosthetic valve function at 12 months. Transcatheter aortic valve replacement successfully treated a prohibitive-risk patient with Corynebacterium striatum prosthetic valve endocarditis and severe aortic regurgitation, with normal valve function at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: